{
    "clinical_study": {
        "@rank": "50169", 
        "arm_group": {
            "arm_group_label": "Stereotactic Body Radiation Therapy", 
            "arm_group_type": "Experimental", 
            "description": "All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice."
        }, 
        "brief_summary": {
            "textblock": "This is a prospective Phase II study.The purpose of this study is to monitor the side\n      effects and treatment outcomes of delivering higher doses of radiation therapy to the\n      tumour, while limiting the dose of radiation to the normal tissues. This will be done using\n      a 5 day treatment schedule.\n\n      The characteristics of patients whose disease remains confined to limited areas in the long\n      term, compared with those who do not will also be described."
        }, 
        "brief_title": "5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases", 
        "completion_date": {
            "#text": "March 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors With Oligometastatic Spread", 
        "detailed_description": {
            "textblock": "Endpoints are to describe:  the proportion of patients with local control for the index site\n      at 1 year; the number of index lesion(s) with local control at 1 year; acute and late AEs\n      related to SBRT; time to local progression for the index site; time to distant disease\n      progression; symptom and QoL profile; median survival."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Any solid tumors are eligible. Lymphoma, myeloma and germ cell tumors are excluded.\n\n          -  Histological confirmation of neoplastic disease either from original primary or\n             metastatic sites is required.\n\n          -  Radiological diagnosis of oligometastastic metastatic disease is accepted if\n             considered clinically acceptable. Histological confirmation is not mandatory.\n\n          -  Oligometastatic disease, maximum of 5 lesions.\n\n          -  At least one lesion is suitable for stereotactic body radiotherapy\n\n          -  All known sites of disease have plans for local ablative management (see section\n             management plan for definitions) within 3 months\n\n          -  ECOG \u2264 2\n\n          -  At least 18 yrs old\n\n        Exclusion Criteria:\n\n          -  Previous radiotherapy to the intended treatment site\n\n          -  Patient cannot tolerate physical set up required for SBRT\n\n          -  Active bowel obstruction, if treating abdominal/pelvic site\n\n          -  Chemotherapy within 2 weeks of intended radiation therapy\n\n          -  Treatment plan respecting normal tissue tolerances using dose fractionation specified\n             within the protocol cannot be achieved\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01761929", 
            "org_study_id": "11-0886-C"
        }, 
        "intervention": {
            "arm_group_label": "Stereotactic Body Radiation Therapy", 
            "description": "All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.", 
            "intervention_name": "Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "oligometastatic", 
            "oligometastases", 
            "stereotactic body radiotherapy", 
            "radiation therapy", 
            "Oligometastasis", 
            "Stereotactic ablative body", 
            "radiotherapy"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "contact": {
                "email": "Rebecca.Wong@rmp.uhn.on.ca", 
                "last_name": "Rebecca K.S. Wong, MB ChB", 
                "phone": "416 946 4501", 
                "phone_ext": "2126"
            }, 
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5G 2M9"
                }, 
                "name": "University Health Network, Princess Margaret Cancer Center"
            }, 
            "investigator": {
                "last_name": "Rebecca Wong, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study on the Toxicity and Efficacy of a Normal Tissue Tolerance Adapted, 5 Fraction Stereotactic Body Radiation Therapy (SBRT) Regimen, for Extra-Cranial Oligometastases", 
        "other_outcome": [
            {
                "measure": "Explore pre-treatment prognostic factors derived from clinical data and correlative studies for disease free interval", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }, 
            {
                "measure": "Explore pre-treatment prognostic factors derived from clinical data and correlative studies for local control of index site(s) at 1 year", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }
        ], 
        "overall_contact": {
            "email": "Rebecca.wong@rmp.uhn.on.ca", 
            "last_name": "Rebecca K.S. Wong, MB ChB", 
            "phone": "416-946-4501", 
            "phone_ext": "2126"
        }, 
        "overall_official": {
            "affiliation": "University Health Network - Princess Margaret Cancer Center", 
            "last_name": "Rebecca K.S. Wong, MB ChB", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2022", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CT will be used for evaluation of the status of the local disease at the index site.", 
            "measure": "Proportion of patients with lack of progressive disease for the index site at 1 year", 
            "safety_issue": "No", 
            "time_frame": "10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01761929"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Modified Response Evaluation Criteria for solid Tumors (RECIST) will be used. By measuring the longest diameter (LD) of the lesions, response of individual lesions and overall response will be documented.", 
                "measure": "Number of index lesion(s) with lack of progressive disease at 1 year.", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }, 
            {
                "description": "Acute toxicity will be graded according to the Common Toxicity Criteria, v4.0", 
                "measure": "Acute toxicity within 90 days of first fraction of radiotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "10 years"
            }, 
            {
                "measure": "Time to local progression for the index site(s)", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }, 
            {
                "measure": "Time to distant disease progression (beyond known sites of oligometastases at time of study entry)", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }, 
            {
                "description": "Late toxicity will be graded according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer score.", 
                "measure": "Late toxicity occuring beyond 90 days related to SBRT.", 
                "safety_issue": "No", 
                "time_frame": "10 year"
            }, 
            {
                "measure": "Describe symptom profile", 
                "safety_issue": "No", 
                "time_frame": "10 Years"
            }, 
            {
                "measure": "Examine radiotherapy parameters (outlined in Appendix J) for local control of index site(s) and toxicities", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }
        ], 
        "source": "University Health Network, Toronto", 
        "sponsors": {
            "collaborator": {
                "agency": "Princess Margaret Hospital, Canada", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University Health Network, Toronto", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}